Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Go back to Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder| (NASDAQ: VTGN) | Delayed: 0.64 -0.03 (4.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.67 | 52 Week High | $4.60 | |||
| Open | $0.71 | 52 Week Low | $2.81 | |||
| Day High | $0.71 | P/E | N/A | |||
| Day Low | $0.64 | EPS | $0.00 | |||
| Volume | 779,168 | |||||
